Clinical Trials Browser

Phase 2 × Pancreatic Neoplasms × pertuzumab × Clear all

NCT01108458 2017-03-03

A Phase 2 Study of Pertuzumab and Erlotinib for Refractory Pancreatic Adenocarcinoma

Phase 2 Terminated

1 enrolled 4 charts

Gastrointestinal

Pancreatic Neoplasms